摘要
目的观察奥扎格雷钠和低分子肝素钙治疗糖尿病下肢动脉疾病的疗效和安全性。方法 64例糖尿病伴下肢严重动脉狭窄的患者,随机分为奥扎格雷钠组和低分子肝素钙治疗组,所有患者在全身情况稳定的基础上,分别接受奥扎格雷钠和低分子肝素钙治疗2周,观察治疗前后腘动脉收缩期峰值血流速度(PSV)和踝肱指数(ABI),安全性评估指标包括活化部分凝血酶时间(APTT)和凝血酶原时间(PT)。结果两组患者治疗前后腘动脉PSV变化值比较差异显著,其中奥扎格雷钠组PSV增加(7.29±8.81)cm/s,低分子肝素钙组PSV增加(13.55±13.11)cm/s,组间差异具有统计学意义(P<0.05):两组治疗前后ABd变化值分别为(0.07±0.07)和(0.08±0.06),组间差异具有统计学意义(P<0.05);但两组患者治疗前后APTT和PT比较差异均无统计学意义。且药物不良反应轻。结论两种抗凝治疗均能显著改善糖尿病下肢动脉血流,且低分子肝素钙疗效优于奥扎格雷钠。
Objective To evaluate the efficacy and safety of ozagrel sodium and low molecular heparin calcium on integrated treatment to diabetic patients with peripheral artery disease. Methods Diabetic patients with peripheral artery disease were randomly divided into ozagrel sodium group and low molecular heparin calcium group. Under intensive blood glucose control and regular treatment to other complications, ozagrel sodium and low molecular heparin calcium were used for 2 weeks in either group. The peak systolic velocity （PSV） of posterior tibial artery and ankle brachial index （ABI） were measured before and at the end of treatment. Activated partial thromboplastin time （APTT） and prothrombin （PT） were tested as safe index. Results After 2 weeks treatment with ozagrel sodium and low molecular heparin calcium, PSV of posterior tibial artery were increased in both groups （P〈0.05）. Compared with low molecular heparin calcium group, increased PSV of ozagrel sodium group was less （7.29±8.81 cm/s vs 13.55±13.11 cm/s, P〈0.05）. ABI changes were significantly different （0.07±0.07 vs 0.08±0.06, P〈0.05）. The changes of APTT and PT had no statistically difference before and after treatment or between two groups. Conclusion Two kinds of anticoagulant therapy can improve low limb blood supply in diabetic PAD patients, but the efficacy of low molecular heparin calcium is better than that of ozagrel sodium.
出处
《世界临床药物》
CAS
2012年第7期412-415,共4页
World Clinical Drug
